DIAGNOSTIC AND THERAPEUTIC CENTER OF ATHENS HYGEIA SA GROUP OF COMPANIES

Condensed Interim Financial Statements for September 30, 2012

(January 1 – September 30, 2012)

prepared in accordance with the International Financial Reporting Standards (IFRS)

The Condensed Financial Statements attached herein, which pertain to the period January 1, 2012 – September 30, 2012, have been prepared in accordance with Article 6 of Law 3556/2007 and were approved by the BoD of the DIAGNOSTIC AND THERAPEUTIC CENTER OF ATHENS HYGEIA SOCIETE ANONYME (hereinafter DTCA HYGEIA SA) on November 21, 2012. They have also been posted on the internet, on the website www.hygeia.gr, where they will be available to investors for at least five (5) years from the date they were prepared and released.

Note that the condensed financial data and information published in the press seek to provide the reader with certain general financial information, but do not provide a complete picture of the financial position and results of the Company and Group, in accordance with the International Financial Reporting Standards.

CONTENTS

Page

Interim Financial Statements

I. Condensed Interim Financial Statements for the period ended September 30, 2012

A) Condensed Financial Position Statement on September 30, 2012

Amounts in € '000		GROUP		COMPANY	
	Note	30/9/2012	31/12/2011	30/9/2012	31/12/2011
ASSETS					
Non-Current Assets					
Tangible assets	7	250,097	256,494	96,234	100,172
Goodwill		168,914	168,914	0	0
Intangible assets	8	132,271	133,496	2,558	2,686
Investments in subsidiaries	9	0	0	323,108	305,958
Investment portfolio		216	216	0	0
Investment in properties		160	162	160	162
Other non current assets		562	548	237	17,354
Deferred tax asset		3,716	3,517	1,890	1,960
Total		**555,936**	**563,347**	**424,187**	**428,292**
Current Assets					
Inventories		6,775	7,502	1,716	1,753
Trade and other receivables	10	103,813	74,716	74,474	58,115
Other current assets	11	13,171	12,989	6,509	4,587
Trading portfolio and financial assets measured at fair value through P&L		85	85	0	0
Cash and cash equivalents	12	32,125	37,375	27,864	29,566
Total		**155,969**	**132,667**	**110,563**	**94,021**
Total Assets		**711,905**	**696,014**	**534,750**	**522,313**
EQUITY AND LIABILITIES					
Equity					
Share capital	13	125,350	125,350	125,350	125,350
Share premium		303,112	303,112	303,112	303,112
Fair value reserves		(14)	(14)	0	0
Other reserves		5,492	5,657	5,134	5,134
Retained earnings		(111,142)	(99,768)	(58,940)	(61,945)
Equity attributable to parent's shareholders		**322,798**	**334,337**	**374,656**	**371,651**
Non-controlling interests		15,585	19,014		
Total Equity		**338,383**	**353,351**	**374,656**	**371,651**
Non-current liabilities					
Deferred tax liability		48,116	47,949	8,409	8,453
Accrued pension and retirement obligations		11,780	11,078	7,052	6,482
Government grants		469	590	0	0
Long-term borrowings	14	105,757	11,524	95,000	0
Non-Current Provisions		11,811	11,270	1,839	1,839
Other long-term liabilities		701	591	54	57
Total		**178,634**	**83,002**	**112,354**	**16,831**
Current Liabilities					
Trade and other payables	15	68,885	58,711	36,419	31,038
Tax payable		1,795	1,240	1,068	539
Short-term debt	14	95,810	180,974	0	95,000
Current portion of non-current provisions		341	336	0	0
Other current liabilities		28,057	18,400	10,253	7,254
Total		**194,888**	**259,661**	**47,740**	**133,831**
Total liabilities		**373,522**	**342,663**	**160,094**	**150,662**
Total Equity and Liabilities		**711,905**	**696,014**	**534,750**	**522,313**

The attached notes form an integral part of the condensed interim Financial Statements.

B) Condensed Comprehensive Income Statement of the Group for the period ended September 30, 2012

Amounts in € '000	Note	GROUP			
		1/1-30/9/2012	1/1-30/9/2011	1/7-30/9/2012	1/7-30/9/2011
Continuing operations					
Sales		184,511	184,183	56,692	55,972
Cost of sales		(166,486)	(176,064)	(53,331)	(56,232)
Gross profit		**18,025**	**8,119**	**3,361**	**(260)**
Administrative expenses		(20,621)	(19,896)	(7,035)	(6,146)
Distribution expenses		(3,659)	(4,150)	(1,135)	(1,334)
Other income		5,205	6,028	1,475	1,204
Other expenses		(1,782)	(2,482)	(442)	(448)
Operating profit / (loss)		**(2,832)**	**(12,381)**	**(3,776)**	**(6,984)**
Other financial results		(386)	(416)	(377)	280
Finance costs		(10,300)	(11,567)	(3,520)	(4,050)
Financial income		545	514	165	152
Profit / (loss) before income tax		**(12,973)**	**(23,850)**	**(7,508)**	**(10,602)**
Income tax	16	(1,742)	(1,267)	283	(785)
Profit / (loss) after tax for the period from continuing operations		**(14,715)**	**(25,117)**	**(7,225)**	**(11,387)**
Discontinued operations					
Net profit / (loss) from discontinued operations		0	(7,077)	0	0
Net profit / (loss) for the period		**(14,715)**	**(32,194)**	**(7,225)**	**(11,387)**
Attributable to:					
Owners of the parent		(12,027)	(21,175)	(6,461)	(10,186)
Non-controlling interests		(2,688)	(3,942)	(764)	(1,201)
Results from discontinued operations Attributable to:					
Owners of the parent		0	(6,244)	0	0
Non-controlling interests		0	(833)	0	0
Profit before taxes, interest & depreciation		12,393	1,861	1,391	(2,060)
Profit before taxes, interest & depreciation (Circ. 34)		12,298	1,692	1,362	(2,101)

Statement of Comprehensive Income

Amounts in € '000	Note	1/1-30/9/2012	1/1-30/9/2011	1/7-30/9/2012	1/7-30/9/2011
Net profit / (loss) for the period after tax		**(14,715)**	**(32,194)**	**(7,225)**	**(11,387)**
Other comprehensive income:					
Exchange differences on translating foreign operations		(214)	27	(331)	60
Exchange gain /(loss) on disposal of foreign operations recognized to profit or loss		0	427	0	0
Other comprehensive income for the period before tax		**(214)**	**454**	**(331)**	**60**
Income tax relating to components of other comprehensive income		0	0	0	0
Other comprehensive income for the period, net of tax		**(214)**	**454**	**(331)**	**60**
Total comprehensive income for the period after tax		**(14,929)**	**(31,740)**	**(7,556)**	**(11,327)**
Attributable to:					
Owners of the parent		(12,192)	(27,271)	(6,751)	(10,137)
Non-controlling interests		(2,737)	(4,469)	(805)	(1,190)
Earnings per share					
Basic earnings per share from continuing operations	19	(0.0393)	(0.1204)	(0.0211)	(0.0579)
Basic earnings per share from discontinued operations	19	0.0000	(0.0355)	0.0000	0.0000
Basic earnings per share	19	**(0.0393)**	**(0.1559)**	**(0.0211)**	**(0.0579)**

The attached notes form an integral part of the condensed interim Financial Statements.

Condensed Comprehensive Income Statement of the Company for the period ended September 30, 2012

Amounts in € '000		COMPANY			
	Note	1/1-30/9/2012	1/1-30/9/2011	1/7-30/9/2012	1/7-30/9/2011
Continuing operations					
Sales		102,902	107,134	30,252	31,594
Cost of sales		(88,215)	(91,559)	(27,930)	(28,309)
Gross profit		**14,687**	**15,575**	**2,322**	**3,285**
Administrative expenses		(5,750)	(5,683)	(1,902)	(1,908)
Distribution expenses		(721)	(747)	(282)	(212)
Other income		1,036	1,317	278	379
Other expenses		(447)	(611)	(33)	(78)
Operating profit / (loss)		**8,805**	**9,851**	**383**	**1,466**
Other financial results		(14)	(5,765)	(31)	0
Finance costs		(5,220)	(7,063)	(1,775)	(2,368)
Financial income		497	435	156	140
Income from dividends		91	46	0	0
Profit / (loss) before income tax		**4,159**	**(2,496)**	**(1,267)**	**(762)**
Income tax	16	(1,154)	(445)	385	(508)
Profit / (loss) for the period after tax		**3,005**	**(2,941)**	**(882)**	**(1,270)**
Profit before taxes, interest & depreciation		15,734	15,801	2,738	3,501
Profit before taxes, interest & depreciation (Circ. 34)		15,565	15,769	2,588	3,491

Statement of Comprehensive Income

Amounts in € '000		1/1-30/9/2012	1/1-30/9/2011	1/7-30/9/2012	1/7-30/9/2011
Net profit / (loss) for the period after tax		**3,005**	**(2,941)**	**(882)**	**(1,270)**
Other comprehensive income for the period, net of tax		**0**	**0**	**0**	**0**
Total comprehensive income for the period after tax		**3,005**	**(2,941)**	**(882)**	**(1,270)**
Earnings per share					
Basic earnings per share	19	**0.0098**	**(0.0167)**	**(0.0029)**	**(0.0072)**

The attached notes form an integral part of the condensed interim Financial Statements.

C) Condensed Changes in Equity Statement for the period ended September 30, 2012

GROUP

Amounts in € '000	Number of shares	Share capital	Share premium	Revaluation reserves	Other reserves	Retained earnings	Total equity attributable to owners of the parent	Minority interests	Total Equity
Balance as of 1/1/2012	**175,861,651**	**72,103**	**292,422**	**(14)**	**5,375**	**(64,178)**	**305,708**	**20,441**	**326,149**
Additional equity offering costs		0	(707)	0	0	0	(707)	0	(707)
Deferred tax		0	(23)	0	0	0	(23)	0	(23)
Dividends to non-controlling interests of subsidiaries		0	0	0	0	0	0	(20)	(20)
Decrease in non-controlling interests due to sale of interest in subsidiaries		0	0	0	0	0	0	4,598	4,598
Transactions with owners	**0**	**0**	**(730)**	**0**	**0**	**0**	**(730)**	**4,578**	**3,848**
Profit for the period		**0**	**0**	**0**	**0**	**(27,419)**	**(27,419)**	**(4,775)**	**(32,194)**
Other comprehensive income:									
Exchange differences on translation of foreign operations		0	0	0	(65)	0	(65)	92	27
Exchange gain/(loss) on disposal of foreign operations recognised in profit or loss		0	0	0	213	0	213	214	427
Other comprehensive income after tax		**0**	**0**	**0**	**148**	**0**	**148**	**306**	**454**
Total comprehensive income for the period after tax	**0**	**0**	**0**	**0**	**148**	**(27,419)**	**(27,271)**	**(4,469)**	**(31,740)**
Balance as of 30/9/2011	**175,861,651**	**72,103**	**291,692**	**(14)**	**5,523**	**(91,597)**	**277,707**	**20,550**	**298,257**
Balance as of 1/1/2012	**305,732,436**	**125,350**	**303,112**	**(14)**	**5,657**	**(99,768)**	**334,337**	**19,014**	**353,351**
Icrease/(decrease) of non-controlling interests in subsidiaries		0	0	0	0	653	653	(653)	0
Dividends to non controlling interests		0	0	0	0	0	0	(39)	(39)
Transactions with owners	**0**	**0**	**0**	**0**	**0**	**653**	**653**	**(692)**	**(39)**
Profit for the period		**0**	**0**	**0**	**0**	**(12,027)**	**(12,027)**	**(2,688)**	**(14,715)**
Other comprehensive income:									
Exchange differences on translation of foreign operations		0	0	0	(165)	0	(165)	(49)	(214)
Other comprehensive income after tax		**0**	**0**	**0**	**(165)**	**0**	**(165)**	**(49)**	**(214)**
Total comprehensive income for the period after tax		**0**	**0**	**0**	**(165)**	**(12,027)**	**(12,192)**	**(2,737)**	**(14,929)**
Balance as of 30/9/2012	**305,732,436**	**125,350**	**303,112**	**(14)**	**5,492**	**(111,142)**	**322,798**	**15,585**	**338,383**

COMPANY

Amounts in € '000	Number of shares	Share capital	Share premium	Other reserves	Retained earnings	Total equity attributable to owners of the parent	Total Equity
Balance as of 1/1/2012	**175,861,651**	**72,103**	**292,422**	**5,134**	**(49,546)**	**320,112**	**320,112**
Additional equity offering costs		0	(707)	0	0	(707)	(707)
Deferred tax		0	(23)	0	0	(23)	(23)
Transactions with owners		**0**	**(730)**	**0**	**0**	**(730)**	**(730)**
Profit for the period		**0**	**0**	**0**	**(2,941)**	**(2,941)**	**(2,941)**
Other comprehensive income:							
Other comprehensive income after tax		**0**	**0**	**148**	**0**	**148**	**454**
Total comprehensive income for the period after tax		**0**	**0**	**148**	**(2,941)**	**(2,793)**	**(2,487)**
Balance as of 30/9/2011	**175,861,651**	**72,103**	**291,692**	**5,134**	**(52,488)**	**316,441**	**316,441**
Balance as of 1/1/2012	**305,732,436**	**125,350**	**303,112**	**5,134**	**(61,945)**	**371,651**	**371,651**
Transactions with owners	**0**	**0**	**0**	**0**	**0**	**0**	**0**
Profit for the period		**0**	**0**	**0**	**3,005**	**3,005**	**3,005**
Other comprehensive income:							
Other comprehensive income after tax		**0**	**0**	**0**	**0**	**0**	**0**
Total comprehensive income for the period after tax		**0**	**0**	**0**	**3,005**	**3,005**	**3,005**
Balance as of 30/9/2012	**305,732,436**	**125,350**	**303,112**	**5,134**	**(58,940)**	**374,656**	**374,656**

The attached notes form an integral part of the condensed interim Financial Statements.

D) Condensed Cash Flow Statement for the period ended September 30, 2012

Amounts in € '000	Note	GROUP 30/9/2012	GROUP 30/9/2011	COMPANY 30/9/2012	COMPANY 30/9/2011
Cash flows from operating activities					
Profit (loss) before taxation from continuing operation		**(12,973)**	**(23,850)**	**4,159**	**(2,496)**
Profit (loss) before taxation from discontinued operation		**0**	**(6,945)**	**0**	**0**
Adjustments for:					
Depreciation		15,225	14,242	6,929	5,950
Changes in pension obligations		1,142	950	570	570
Provisions		1,947	2,002	1,035	1,044
Unrealized Exchange gains		(123)	(479)	0	0
Unrealized Exchange losses		359	1,019	14	0
(Profit) loss on sale of property, plant and equipment		26	(46)	(139)	(2)
(Profit) loss on sale of intagible assets		0	3	0	0
Income from reversal of prior year's provisions		(198)	(739)	0	0
Proft / Loss from fair value valuation of financial assets at fair value through profit and loss		150	0	0	0
Grants amortization		(121)	(123)	(30)	(30)
Non-cash compensation expense		0	4	0	0
Interest and similar income		(545)	(514)	(497)	(435)
Interest similar expenses		10,146	11,465	5,220	7,063
Dividends		0	0	(91)	(46)
Profit/Loss from sale of subsidiary		0	0	0	5,765
Total Adjustments		**28,008**	**27,784**	**13,011**	**19,879**
Cash flows from operating activities before working capital changes		**15,035**	**(3,011)**	**17,170**	**17,383**
Changes in Working Capital					
(Increase) / Decrease in inventories		566	1,153	36	785
(Increase)/Decrease in trade receivables		(29,725)	(995)	(15,506)	(9,113)
(Increase)/Decrease in other receivables		(527)	5,050	(3,061)	281
Increase / (Decrease) in liabilities (excluding banks		18,307	(5,263)	7,512	(2,228)
Operating cash flows from discontinued operations		0	6,835	0	
		(11,379)	***6,780***	***(11,019)***	***(10,275)***
Cash flows operating activities		**3,656**	**3,769**	**6,151**	**7,108**
Interest paid		(10,105)	(10,792)	(5,563)	(6,489)
Income tax paid		(270)	(2,385)	0	(463)
Net Cash flows operating activities		**(6,719)**	**(9,408)**	**588**	**156**
Cash flows from investing activities					
Purchase of property, plant and equipment	7	(6,821)	(10,142)	(3,437)	(4,890)
Purchase of intagible assets	8	(1,206)	(517)	(702)	(476)
Proceeds from disposal of property, plant and equipment		25	212	1,414	31
Increase in capital and additional paid-in capital of subsidiaries		0	0	0	(76)
Dividends received		0	0	50	36
Sale of subsidiaries (less cash)		0	6,542	0	6,931
Interest received		432	281	385	176
Grants received		21	0	0	0
Loans to related parties		0	0	0	(125)
Receivables from loans to related parties		0	0	0	9,025
Investment cash flows from discontinued operations		0	2,049	0	0
Net Cash flow from investing activities		**(7,549)**	**(1,575)**	**(2,290)**	**10,632**
Cash flow from financing activities					
Additional equity offering costs		0	(707)	0	(707)
Proceeds from borrowings		31,247	93,529	0	60,000
Payments for borrowings		(21,551)	(77,556)	0	(67,000)
Dividends paid to non-controlling interests		(39)	(20)	0	0
Payment of finance lease liabilities		(627)	(590)	0	0
Financing activities cash flows from discontinued operations		0	(2,099)	0	0
Net Cash flow financing activities		**9,030**	**12,557**	**0**	**(7,707)**
Net (decrease) / increase in cash and cash equivalents		**(5,238)**	**1,574**	**(1,702)**	**3,081**
Cash and cash equivalents at beginning of the period from continuing operations		37,375	35,469	29,566	27,001
Cash and cash equivalents at beginning of the period from discontinued operations		0	582	0	0
Exchange differences in cash and cash equivalents from continuing operations		(12)	(53)	0	0
Exchange differences in cash and cash equivalents from discontinued operations		0	(33)	0	0
Net cash and cash equivalents at the end of the period from continuing operations		**32,125**	**37,539**	**27,864**	**30,082**

The attached notes form an integral part of the condensed interim Financial Statements.

II. Notes on the Condensed Interim Financial Statements for the period ended September 30, 2012

1. General Information about the Group

HYGEIA SA was founded in 1970 by physicians, the majority of whom were professors at the University of Athens, and has since been active in the provision of primary and secondary healthcare services.

The issuing Company is housed in a private building situated on the corner of 4 Erythrou Stavrou Street and Kifisias Avenue in Marousi, Attica, which is renovated accordingly from time to time. HYGEIA Group's financial services are located on the corner of 21 Ippokratous Street and Erythrou Stavrou Street in Marousi, Attica (Postcode: 151 23). The Company's internet address is www.hygeia.gr and its shares are listed on the Athens Stock Exchange.

In January 2006, MARFIN INVESTMENT GROUP (MIG) gained control of the Company and within the next few months, it launched a series of investment initiatives (acquisitions, mergers and the establishment of new companies), with the strategic objective to create the largest group of integrated healthcare services in Southeast Europe. On September 30th, 2012, HYGEIA Group was present in 3 Southeast European countries, owning a total of 6 private hospitals in Greece, Albania and Cyprus, with a total capacity of 1,422 licensed beds, 69 operating rooms, 40 delivery rooms and 11 ICUs, and employing approximately 3,400 people and over 4,000 associate physicians.

The Company's portfolio includes the following hospitals: DTCA HYGEIA; MITERA Maternity, Gynecological & Children's Hospital; LETO Maternity Hospital; ACHILLION Hospital in Lemesos, Cyprus; EVANGELISMOS Hospital in Paphos, Cyprus; and HYGEIA Hospital Tirana.

HYGEIA Group is active in the area of primary healthcare through the ALPHA-LAB Molecular Biology and Cytogenetics Center, the Athens Bio-check International Clinic and the West Athens Primary Medical Care Clinic.

Moreover, in July 2008, HYGEIA Group expanded towards the stem-cell banking sector, establishing subsidiary STEM-HEALTH HELLAS SA. Finally, HYGEIA Group owns a company trading in special materials, consumables, pharmaceuticals and general medical supplies (Y-LOGIMED SA).

HYGEIA SA offers its services to private individuals as well as patients seeking top-quality healthcare services through their social security funds and insurance companies. Throughout its history, and adhering to the principle of sustainable development, the Group has been endeavoring to combine top-level healthcare services, with a deep sense of respect for people, the society and the environment.

HYGEIA Group is a subsidiary of **MARFIN INVESTMENT GROUP SA (MIG)**.

On September 30th, 2012, HYGEIA SA employed a total of 1,284 people, as opposed to 1,257 on September 30th, 2011, while the Group employed a total of 3,406 people, as opposed to 3,408 on September 30th, 2011.

2. Structure and activities of the Group companies

The Group companies included in the consolidated financial statements are as follows:

No.	Company Name	Registered in	Activity	Holding %	Consolidation Method	Holding R/ship	Open Fiscal Years
1	**DTCA HYGEIA SA**	**Greece**	**Healthcare services**		**PARENT COMPANY**		**2009-2011**
	HYGEIA Subsidiaries						
2	MITERA SA	Greece	Healthcare services	99,05%	Full consolidation	Direct & Indirect	2008-2011
3	MITERA HOLDINGS SA	Greece	Holdings in MITERA SA	100%	Full consolidation	Direct	2010-2011
4	LETO SA	Greece	Healthcare services	87,88%	Full consolidation	Indirect	2008-2011
5	LETO HOLDINGS SA	Greece	Holdings in LETO SA	87,78%	Full consolidation	Indirect	2010-2011
6	ALPHA-LAB SA	Greece	Healthcare services	87,78%	Full consolidation	Indirect	2010-2011
7	HYGEIA HOSPITAL TIRANA ShA	Albania	Healthcare services	87,86%	Full consolidation	Direct	-
8	VALLONE CO LTD	Cyprus	Investment	100,00%	Full consolidation	Direct & Indirect	-
9	CHRYSAFILIOTISSA INVESTMENT LTD	Cyprus	Investment	79,07%	Full consolidation	Indirect	-
10	CHRYSAFILIOTISSA PUBLIC LTD	Cyprus	Real estate and equipment	65,76%	Full consolidation	Indirect	-
11	LIMASSOL ACHILLEIO MEDICAL CENTRE LTD	Cyprus	Healthcare services	65,76%	Full consolidation	Indirect	-
12	EVANGELISMOS MATERNITY GYNECOLOGICAL CLINIC LTD	Cyprus	Investment	100,00%	Full consolidation	Direct	-
13	EVANGELISMOS MANAGEMENT LTD	Cyprus	Healthcare services	97,32%	Full consolidation	Indirect	-
14	AKESO PROPERTY LTD	Cyprus	Investment	60,00%	Full consolidation	Indirect	-
15	EVANGELISMOS PROPERTY LTD	Cyprus	Investment	60,00%	Full consolidation	Indirect	-
16	STEM HEALTH SA	Greece	Stem cell medical technology	50,00%	Full consolidation	Direct	2010-2011
17	STEM HEALTH HELLAS SA	Greece	Stem cell medical technology	74,53%	Full consolidation	Indirect	2010-2011
18	Y-LOGIMED SA	Greece	Import, trading and supply of medical technology products	100,00%	Full consolidation	Direct	2010-2011
19	Y-LOGIMED Sh.p.k.	Albania	Import, trading and supply of medical technology products	100,00%	Full consolidation	Indirect	-
20	Y-PHARMA SA	Greece	Trading of pharmaceuticals and general medical supplies	85,00%	Full consolidation	Direct	2010-2011
21	ANIZ SA	Greece	Operation of canteens and restaurants	70,00%	Full consolidation	Direct	2010-2011
22	BIO-CHECK INTERNATIONAL PRIVATE CLINIC SA	Greece	Healthcare services	100,00%	Full consolidation	Indirect	2010-2011
23	WEST ATHENS PRIVATE CLINIC PRIMARY MEDICINE	Greece	Healthcare services	71,80%	Full consolidation	Indirect	2010-2011

Compared to the same period in 2011, GENESIS Group has not been included in the consolidated Financial Statements for the period ended September 30, 2012, due to a sale agreement and loss of control on February 14th, 2011.

Upon conclusion of the share capital increase of subsidiary HYGEIA Hospital Tirana ShA on March 27, 2012, HYGEIA SA’s direct holding percentage is 87.86% from 80.00%.

Upon conclusion of the share capital increase of subsidiary WEST ATHENS PRIVATE CLINIC PRIMARY MEDICINE SA, HYGEIA SA’s indirect holding percentage is 71.80% from 49.00%.

Furthermore, upon conclusion of the share capital increase of subsidiary EVANGELISMOS MANAGEMENT LTD on June 30, 2012, HYGEIA SA's indirect holding percentage is 97.32% from 60.00%.

3. Basis of presentation of Financial Statements

3.1 Framework for preparing the company and consolidated Financial Statements

The condensed interim and consolidated Financial Statements (hereinafter Financial Statements) for the period ended September 30th, 2012 have been prepared based on the principle of historical cost, as amended with the readjustment of specific assets to fair value, and on the principle of going concern. The Financial Statements are in line with the International Financial Reporting Standards (IFRS), as adopted by the European Union up to and including September 30, 2012, and specifically in line with the requirements of IAS 34 "Interim Financial Reporting".

The Financial Statements for the period ended September 30, 2012 were approved by the Company's BoD on November 21st, 2012.

3.2 Presentation Currency

The presentation currency is the euro (currency of the country where the Group parent company is registered) and all amounts appear in euros, unless otherwise specified.

3.3 Comparability

The financials of the consolidated Comprehensive Income Statement and the consolidated Cash Flow Statement for the period ended September 30th, 2011 have been revised to include continuing operations only.

3.4 Rounding off

Discrepancies between the amounts in the Financial Statements and the corresponding amounts in the Notes are a result of rounding off.

4. Main accounting principles

The condensed interim Financial Statements for the period ended September 30th, 2012 contain limited information compared to the annual Financial Statements. The accounting policies used to prepare the Financial Statements are consistent with those that were used to prepare the Financial Statements for the fiscal year ended December 31st, 2011. Therefore, the interim Financial Statements herein must be studied in combination with the latest published annual Financial Statements for December 31st, 2012, which contain a thorough overview of the accounting policies and valuation methods used.

4.1 New standards, interpretations, revisions and amendments to the existing standards which are in effect and have been adopted by the EU

The following amendments and interpretations of the IFRS were published by the International Accounting Standards Board (IASB) and their application is mandatory as of January 1st, 2012 or thereafter. The most important standards and interpretations are listed below:

- **Amendments to IFRS 7 "Financial instruments": Disclosure requirements for transferring financial instruments (applicable to annual accounting periods commencing on or after July 1, 2011)**

The purpose of this amendment is to permit users of Financial Statements to improve their understanding of financial asset transfer transactions and the possible impacts of any risks which may remain for the entity which has transferred financial assets. Moreover, this amendment requires additional disclosures in the case where a disproportionate amount of transfer transactions has taken place at the end of the reporting period. The Group does not expect that this amendment would have any impact on the consolidated Financial Statements. This amendment was approved by the EU in November 2011.

- **Amendments to IAS 1 "Presentation of Financial Statements" - Presentation of Other Comprehensive Income (applicable to annual accounting periods commencing on or after July 1, 2012)**

In June 2011, the IASB issued amendments to IAS 1 "Presentation of Financial Statements". These amendments refer to the way information about other comprehensive income is presented. The Group will examine the impact of the aforementioned modification on the consolidated Financial Statements. These amendments are applicable to annual accounting periods commencing on or after July 1, 2012. This amendment was approved by the EU in June 2012.

4.2 New standards, interpretations, revisions and amendments to the existing standards which are not yet in effect or have not been approved by the EU

The following new standards and revisions to standards, as well as the following interpretations for existing standards, have been published, but either they are not yet in effect or they have not been approved yet by the EU. In particular:

- **Amendment to IAS 12 "Deferred tax: Recovery of underlying assets" (applicable to annual accounting periods commencing on or after January 1, 2012)**

This amendment to IAS 12 "Income Taxes" was issued in December 2010. It provides useful guidelines for the cases of assets measured at fair values, in accordance with the requirements of IAS 40 "Investment Property", for property recovered through use or sale. This amendment is applicable to annual accounting periods commencing on or after July 1, 2011. Earlier application is permitted. The Group will examine the impact of the aforementioned modification on the consolidated Financial Statements. This amendment has not yet been approved by the EU.

- **Amendment to IFRS 1 "First-time Adoption of International Financial Reporting Standards" - Severe Hyperinflation and Removal of Fixed Dates for First-time Adopters of IFRS (applicable to annual accounting periods commencing on or after July 1, 2011)**

The relevant amendments to IFRS 1 "First-time Adoption of International Financial Reporting Standards" were issued in December 2010. The amendments replace references to fixed dates with regard to first-time adopters of the IFRS with the term "the date of transition to IFRS". They set the conditions with regard to how a company must present its Financial Statements in accordance with the IFRS after a period whereby the company was not able to comply with IFRS requirements because its operating currency had been subject to severe hyperinflation. The amendments apply as of July 1, 2011. Earlier application is permitted. The Group will examine the impact of the aforementioned modification on the consolidated Financial Statements. This amendment has not yet been approved by the EU.

- **IFRS 9 "Financial Instruments" (applicable to annual accounting periods commencing on or after January 1, 2015)**

On November 12, 2009, the IASB issued a new standard, the revised IFRS 9 "Financial Instruments", which will gradually replace IAS 39 "Financial Instruments: Recognition and Measurement". Note that in October 2010, the IASB issued additions with regard to the financial liabilities that a financial entity has chosen to measure in fair values. According to IFRS 9, all financial assets are initially measured at fair value plus transaction costs. Subsequent measurement of financial assets is either performed at amortized cost or at fair value, depending on the company's business model with regard to its financial assets and the contractual cash flows of said asset. IFRS 9 does not allow reclassifications, except for the cases where the company's business model has changed, but even in that case, the company must reclassify all affected financial instruments in the future. According to the IFRS 9 principles, all equity investments should be measured at fair value. However, the Management has an option to present in other comprehensive income realized and unrealized fair value earnings and losses on equity investments that are not held for trading. The Group will examine the impact of the aforementioned modification on the consolidated Financial Statements. This standard has not yet been adopted by the EU.

- **IFRS 10 "Consolidated Financial Statements", IFRS 11 "Joint Arrangements", IFRS 12 "Disclosures of interests in other entities", IAS 27 "Separate Financial Statements" and IAS 28 "Investments in Associates and Joint Ventures" (applicable to annual accounting periods commencing on or after January 1, 2013)**

In May 2011, the IASB issued three new standards, specifically IFRS 10, IFRS 11 and IFRS 12. IFRS 10 "Consolidated Financial Statements" introduces a single consolidation model for all entities based on control. IFRS 10 replaces IAS 27 "Consolidated and Separate Financial Statements" and SIC 12 "Consolidation - Special purpose entities". IFRS 11 "Joint Arrangements" outlines the principles with regard to the financial reporting for entities that jointly control an arrangement. IFRS 11 replaces IAS 31 "Interests in Joint Ventures" and SIC 13 "Jointly Controlled Entities - Non-monetary Contributions by Venturers". IFRS 12 "Disclosures of interests in other entities" combines, enhances and replaces disclosure requirements for subsidiaries, jointly controlled entities, associates and unconsolidated structured entities. As a consequence of these new standards, the IASB also issued the amended IAS 27, entitled IAS 27 "Separate Financial Statements", and the amended IAS 28, entitled IAS 28 "Investments in Associates and Joint Ventures". The new standards are applicable to annual accounting periods commencing on or after January 1, 2012, with earlier application permitted. The Group will examine the impact of the aforementioned modification on the consolidated Financial Statements. The aforementioned modifications have not yet been adopted by the EU.

- **IFRS 13 "Fair Value Measurement" (applicable to annual accounting periods commencing on or after January 1, 2013)**

In May 2011, the IASB issued IFRS 13 "Fair Value Measurement". IFRS 13 defines fair value, sets out a single standard a framework for measuring fair value, and requires disclosures about fair value measurements. IFRS 13 is applicable is cases where other IFRSs require or allow fair value measurements. IFRS 13 does not introduce new requirements for measuring the fair value of an asset or liability. Moreover, it does not change what other standards stipulate with regard to which financials are measured at fair value and does not mention how the changes in fair value are to be presented in the Financial Statements. The Group will examine the impact of the aforementioned modification on the consolidated Financial Statements. The new standard is applicable to annual accounting periods commencing on or after January 1, 2013, with earlier application permitted. This standard has not yet been adopted by the EU.

- **Amendments to IAS 19 "Employee Benefits" (applicable to annual accounting periods commencing on or after January 1, 2013)**

In June 2011, the IASB issued amendments to IAS 19 "Employee Benefits". These amendments aim at improving issues relating to recognition and disclosure requirements for defined benefit plans. The new amendments are applicable to annual accounting periods commencing on or after January 1, 2013, with earlier application permitted. The Group will examine the impact of the aforementioned modification on the consolidated Financial Statements. This amendment was approved by the EU in June 2012.

- **IFRIC 20 "Stripping Costs in the Production Phase of a Surface Mine" (applicable to annual accounting periods commencing on or after January 1, 2013)**

In October 2011, the IASB issued IFRIC 20. This interpretation clarifies when production stripping costs should lead to the recognition of an asset and how that asset should be initially and subsequently measured. This interpretation is applicable to annual accounting periods commencing on or after January 1, 2013, with earlier application permitted. Said interpretation is not applicable to the Group's activities. This amendment has not yet been adopted by the EU.

- **Amended IAS 32 "Financial instruments: Presentation" – Offsetting financial assets and financial liabilities (applicable to annual accounting periods commencing on or after January 1, 2014)**

In December 2011, the IASB issued amendments to IAS 32 "Financial Instruments: Presentation" with the aim of clarifying the standard's requirements in the event of offsetting. These amendments are applicable to annual accounting periods commencing on or after January 1, 2014, with earlier application permitted. The

Group will examine the impact of the aforementioned modification on the consolidated Financial Statements. This amendment has not yet been adopted by the EU.

- **Amendments to IFRS 7 "Disclosures" – Offsetting financial assets and financial liabilities (applicable to annual accounting periods commencing on or after July 1, 2013)**

In December 2011, the IASB issued new disclosure, requirements allowing users of Financial Statements to compare in the best possible manner the statements published in accordance to IFRS to those published in accordance with the US GAAP. These amendments are applicable to annual accounting periods commencing on or after January 1, 2013. The Group will examine the impact of the aforementioned modification on the consolidated Financial Statements. This amendment has not yet been adopted by the EU.

- **Amendment to IFRS 1 "First-time Adoption of International Financial Reporting Standards" – Government Loans (applicable to annual accounting periods commencing on or after July 1, 2013)**

In March 2012, the IASB issued the amendment to IFRS 1, whereby first-time adopters of IFRS are relieved from full retrospective application of IFRS when accounting for these loans on transition. The Group will examine the impact of the aforementioned modification on the consolidated Financial Statements. This amendment has not yet been adopted by the EU.

- **Annual Improvements to IFRS 2009-2011 Cycle (issued in May 2012 – the amendments are applicable to the annual accounting periods commencing on or after January 1, 2013)**

In May 2012, the IASB issued the "Annual Improvements to IFRSs 2009-2011 Cycle", which incorporates a series of adjustments to 5 IFRSs and forms part of the annual improvement project. These amendments are not particularly important and do not materially affect the Group's Financial statements. These amendments have not yet been adopted by the EU.

- **Consolidated Financial Statements, Joint Arrangements and Disclosures of Interests in other entities: Transition Guidance (amendments to IFRS 10, IFRS 11 and IFRS 12 – applicable to annual accounting periods commencing on or after January 1, 2013)**

In June 2012, the IASB issued the aforementioned publication, which clarifies the transitional provisions in IFRS 10. Moreover, the amendments provide additional transitional relief in IFRS 10, IFRS 11 and IFRS 12, by limiting the requirement to provide adjusted comparative information to only the preceding comparative period. Furthermore, for disclosures related to unconsolidated structured entities, the amendments will remove the requirement to present comparative information for periods before IFRS 12 is first applied. These amendments are applicable to annual accounting periods commencing on or after January 1st, 2013. The Group will examine the impact of the aforementioned modification on the Group's Financial Statements. These amendments have not yet been adopted by the EU.

5. Accounting estimates and assumptions

In preparing the condensed interim company and consolidated Financial Statements, the significant accounting estimates and assumptions adopted by the Management for applying the Group's accounting policies, as well as the main sources of uncertainly affecting the estimates, are the same as those that had been adopted for preparing the annual Financial Statements for the fiscal year ended December 31st, 2012.

6. Operating segments

The Group implements IFRS 8 "Operating segments", which stipulates that the operating segments are defined based on the "management approach" and requires that external reporting is based on the same principles as internal reporting. The Company's BoD recommended the main business decision-maker and has identified two operating segments for the Group's activities. In particular, the group is active in the healthcare services sector – and specifically the provision of diagnostic and medical treatment services – and the medical supplies, pharmaceuticals and special materials trading sector, mainly within Greece, but also abroad. The required reporting per operating segment is outlined below.

The income, earnings, assets and liabilities per operating segment are as follows:

Sales	**Healthcare Sector**	**Commercial Sector**	**Total from continuing operations**	**Discontinuing operations**	**Total**
- to external customers	180.096	4.415	184.511	0	184.511
- to other sectors	2.454	24.003	26.457	0	26.457
Net Sales	**182.550**	**28.418**	**210.968**	**0**	**210.968**
Depreciation	(14.848)	(377)	**(15.225)**	**0**	**(15.225)**
Financial Income	544	1	**545**	**0**	**545**
Financial Expense	(10.249)	(51)	**(10.300)**	**0**	**(10.300)**
Gains / (Losses) before taxes for the period	(10.534)	(2.439)	**(12.973)**	**0**	**(12.973)**
Total Assets as at 30.09.2012	794.900	38.014	**832.914**	0	**832.914**

Segment Results as of 30.09.2011

Sales	**Healthcare Sector**	**Commercial Sector**	**Total from continuing operations**	**Discontinuing operations**	**Total**
- to external customers	176.067	8.116	184.183	2.157	186.340
- to other sectors	3.095	25.101	28.196	0	28.196
Net Sales	**179.162**	**33.217**	**212.379**	**2.157**	**214.536**
Depreciation	(13.278)	(964)	**(14.242)**	**(172)**	**(14.414)**
Financial Income	482	32	**514**	**58**	**572**
Financial Expense	(11.275)	(292)	**(11.567)**	**(207)**	**(11.774)**
Gains / (Losses) before taxes for the period	(22.146)	(1.704)	**(23.850)**	**(1.107)**	**(24.957)**
Total Assets as at 31.12.2011	772.611	30.686	**803.297**	0	**803.297**

Group sales and assets based on geographical distribution are as follows:

Geographical Segments	**30/9/2012**		**30/9/2011**	
	Sales	**Total Assets**	**Sales**	**Total Assets**
Greece	195,867	749,037	199,551	715,856
Other countries	15,101	83,877	12,828	87,441
Total from continuing operations	**210,968**	**832,914**	**212,379**	**803,297**
Discontinuing operations	0	0	2,157	0
Total	**210,968**	**832,914**	**214,536**	**803,297**

The total amounts corresponding to the Group's operating segments reconcile with the main items in the Financial Statements as follows:

Reconciliation Table

Amounts in € '000

Segment Sales	**30/9/2012**	**30/9/2011**
Total segment sales	210,968	212,379
Eliminations of intrecompany sales	(26,457)	(28,196)
Total from continuing operations	**184,511**	**184,183**
Discontinued operations	0	2,157
Total	**184,511**	**186,340**

Earnings or Losses	**30/9/2012**	**30/9/2011**
Total Earnings / (Losses) for segments	(12,973)	(24,957)
Discontinued operations	0	1,107
Earnings / (Losses) before tax for the period	**(12,973)**	**(23,850)**

Assets	**30/9/2012**	**31/12/2011**
Total segment assets	832,914	803,297
Eliminations of intercompany assets	(121,009)	(107,283)
	711,905	**696,014**

7. Tangible assets

During the closed period, the Group and the Company spent the amount of €6,821 thousand and €3,437 thousand respectively for the purchase of tangible assets, mainly pertaining to medical equipment and renovations.

8. Intangible assets

During the closed period, the Group and the Company spent the amount of €1,206 thousand and €702 thousand respectively for the purchase of intangible assets, mainly pertaining to computer software.

9. Investments in subsidiaries

The change in investments in subsidiaries is due to the fact that HYGEIA participated (€17.15m) in the share capital increase completed by HYGEIA Hospital Tirana ShA on March 27th, 2012.

10. Trade & other receivables

Group and Company trade and other receivables can be broken down as follows:

Amounts in € '000	GROUP		COMPANY	
	30/9/2012	31/12/2011	30/9/2012	31/12/2011
Trade receivables	99,311	64,391	64,032	46,280
Intercompany accounts receivable	0	0	8,227	5,230
Notes receivable	20,370	24,719	13,578	16,618
Checks receivable	1,991	2,500	417	726
Less:Impairment Provisions	(17,929)	(17,044)	(11,780)	(10,739)
Net trade Receivables	**103,743**	**74,566**	**74,474**	**58,115**
Advances from suppliers	70	150	0	0
Total	**103,813**	**74,716**	**74,474**	**58,115**

The increase in third-party trade receivables is mainly due to the commencement of the partnership agreement between the Group companies and the National Organization for Healthcare (EOPYY) on January 1st, 2012, and the payment delays arising from the specific partnership.

11. Other current assets

Other current assets can be broken down as follows:

Amounts in € '000	GROUP		COMPANY	
	30/9/2012	31/12/2011	30/9/2012	31/12/2011
Other Debtors	6,636	7,045	1,620	2,366
Receivables from the State	3,900	7,783	1,739	2,133
Advances and loans to personnel	47	23	0	0
Accrued income	4,151	119	2,909	0
Prepaid expenses	1,604	1,212	455	291
Other Receivables	369	343	163	174
Receivables arising from share disposal	773	773	773	773
Total	**17,480**	**17,298**	**7,659**	**5,737**
Less:Impairment Provisions	(4,309)	(4,309)	(1,150)	(1,150)
Net Receivables	**13,171**	**12,989**	**6,509**	**4,587**

12. Cash and cash equivalents

Bank deposits bear interest at a floating rate, based on the monthly bank deposit interest rates.

The Group's cash, which is currently blocked, amounted to €26.083thousand on September 30th, 2012 (December 31st, 2011: €24.286thousand). The amount has been blocked mainly to secure credit facilities for the Group subsidiaries.

Interest income from sight and term deposits in banks was €504 thousand for the Group (September 30th, 2011: €510 thousand) and €456 thousand for the Company (September 30th, 2011: €433 thousand) and is included in the accounting item "Financial Income".

13. Share capital and premium

The Company's share capital amounts to one hundred and twenty-five million three hundred and fifty thousand two hundred and ninety-nine euros (€125,350,299) fully paid, divided into three hundred and five million seven hundred and thirty-two thousand four hundred and thirty-six (305,732,436) ordinary registered shares at a nominal value of forty-one cents (€0.41) each, all listed on the Athens Stock Exchange.

14. Loans

On September 28th, 2012, the Company signed a common bond loan amounting to €95m with the associated banks Piraeus, Eurobank Ergasias, Emporiki and Alpha Bank. The loan has a floating interest rate based on Euribor plus margin. The loan was taken out to refinance the Company's existing loans to the aforementioned associated banks.

This agreement has been mainly secured via the mortgage underwriting of the Company's property, while it carries the obligation of complying with the financial indicators calculated in the annual and semi-annual Company Financial Statements that have been audited by certified auditors.

As a consequence of signing the aforementioned Common Bond Loan, the Group and the Company have reclassified loans of the same value (€95m) from short-term lending liabilities to long-term lending liabilities.

Upon concluding and signing the aforementioned agreement, the Group is proceeding with refinancing the bank loans of subsidiary "Mitera Private General Maternity Gynecological & Pediatric Hospital SA" with the issuance of a bond loan amounting to approximately €42m.

Furthermore, on September 30th, 2012, subsidiary HYGEIA Hospital Tirana ShA was not in compliance with the financial indicators for bank borrowing to equity and for assets to short-term liabilities; however, it has filed a request to the associated banks asking them for a mutually acceptable waiver from the adherence obligation until September 30th, 2012.

15. Suppliers and other liabilities

Suppliers and other liabilities can be broken down as follows:

Amounts in € '000	GROUP		COMPANY	
	30/9/2012	31/12/2011	30/9/2012	31/12/2011
Suppliers	52,427	45,076	12,059	13,497
Checks Payable	3,366	1,955	2,176	1,142
Customers' Advances	1,060	1,181	873	1,016
Intercompany accounts payable	0	0	13,354	8,828
Other liabilities	12,032	10,499	7,957	6,555
Total	**68,885**	**58,711**	**36,419**	**31,038**

16. Income tax

Group and Company income tax expense for the period January 1, 2012 – September 30, 2012 and the respective period last year can be broken down as follows:

	GROUP				COMPANY	
	Continuing operations		Discontinued operations		Continuing operations	
Amounts in € '000	30/9/2012	30/9/2011	30/9/2012	30/9/2011	30/9/2012	30/9/2011
Current income tax	1,460	1,171	0	0	1,128	482
Deferred incoma tax	(32)	275	0	132	26	556
Tax audit differences	0	0	0	0	0	0
Income tax provision	293	638	0	0	0	225
Other taxes	21	(817)	0	0	0	(817)
Total tax from continuing operations	**1,742**	**1,267**	**0**	**132**	**1,154**	**446**

	GROUP				COMPANY	
	Continuing operations		Discontinued operations		Continuing operations	
Amounts in € '000	**30/9/2012**	**30/9/2011**	**30/9/2012**	**30/9/2011**	**30/9/2012**	**30/9/2011**
Profit before income tax (from continuing and discontinued operations)	(12,973)	(23,850)	0	(1,107)	4,159	(2,496)
Nominal Tax rate	20%	20%	20%	20%	20%	20%
Presumed Tax on Income	**(2,595)**	**(4,770)**	**0**	**(221)**	**832**	**(499)**
Adjustments for non taxable income						
- Damage of the year for which was not recognized deferred tax asset	1,602	4,807	0	221	0	0
- Dividends or profits from participations	(18)	(9)	0	0	(18)	(9)
- Other	0	(37)	0	0	0	0
Adjustments for non deductible expenses for tax purposes						0
- Non tax deductible expenses	368	2,013	0	0	0	0
- Effect on opening deferred income tax of reduction in income tax rates	0	(402)	0	0	0	0
- Other expenses non deductible for tax purposes	1,516	507	0	0	324	502
- Additional taxes and surcharges	114	92	0	0	16	4
- Additional property tax	0	57	0	0	0	0
- Special contribution	0	(817)	0	0	0	(817)
- Effect from differences in tax coefficients of foreign subsidiaries	282	0	0	0	0	0
- Other	473	(174)	0	132	0	1,265
Total tax from continuing and discontinued operations	**1,742**	**1,267**	**0**	**132**	**1,154**	**446**

17. Commitments, contingent liabilities and receivables

17.1. Guarantees

Group and Company guarantees on September 30th, 2012 and December 31st, 2011 were as follows:

	GROUP		COMPANY	
Amounts in € '000	**30/9/2012**	**31/12/2011**	**30/9/2012**	**31/12/2011**
Guarantees				
Guarantees to third parties	1,522	1,522	0	0
Performance letters of guarantee	230	206	0	0
Guarantees for the repayment of subsidiary loans	55,540	54,334	51,390	50,188
Guarantees for the repayment of trade liabilities	113	151	57	92
Performance letters of guarantee for subsidized investment programmes	14	12	10	12
Guarantees for the participation in various tenders	1	1	0	0
Total guarantees	**57,420**	**56,226**	**51,457**	**50,292**

17.2 Encumbrances

On September 30th, 2012, the mortgages registered on HYGEIA properties as collateral against bank loans amounted to €72m.

In addition, on September 30th, 2012, the mortgages registered on HYGEIA Group properties as collateral for bank loans amounted to €34.8m. Specifically, there is a mortgage registered on a property owned by subsidiary HYGEIA Hospital Tirana ShA, amounting to €20m, and mortgages registered on properties owned by the Cypriot subsidiaries, amounting to approximately €14.8m.

17.3 Operating lease commitments

The Group leases offices and warehouses through operating leases, which have different terms, adjustment clauses and rights of renewal. According to the operating lease agreements, the future minimum total rent payable is as follows:

Amounts in € '000	GROUP		COMPANY	
	30/9/2012	**31/12/2011**	**30/9/2012**	**31/12/2011**
Operating lease commitments				
Within one year	2,042	2,219	664	630
After one year but not more than five years	5,943	6,924	1,496	1,262
More than five years	4,146	6,009	553	127
Total operating lease commitments	**12,131**	**15,152**	**2,713**	**2,019**

17.4. Court cases

Major Pending Litigation

HYGEIA
The Company (both as a defendant and as a plaintiff) is involved in various pending court cases as part of its normal operation. These also include medical malpractice cases. For the majority of said cases, the Group is covered for professional malpractice through malpractice liability policies it holds. On September 30th 2012, the Company had formed a provision of €1.4m. The Company's Management and legal advisors estimate that the pending cases, apart from the already formed provision for *sub judice* cases, are expected to be settled without a significant negative impact on the Company's consolidated financial position or its operating results.

MITERA
The company MITERA (both as a defendant and as a plaintiff) is involved in various pending court cases as part of its normal operation. On September 30th, 2012, the Company had formed a provision of €7.46m. The Company's Management and legal advisors estimate that the pending cases, apart from the already formed provision for *sub judice* cases, are expected to be settled without a significant negative impact on the Group's consolidated financial position or its operating results.

Among the aforementioned pending court cases, there is a lawsuit filed by a private maternity hospital against the Company and other maternity hospitals before the Athens Multi-Member Court of First Instance, asking that the Company and the other maternity hospitals be held jointly and severally liable and must be made to pay the amount of €10m as compensation for moral harm. The Company's Management and legal advisors estimate that the said lawsuit will be rejected as unfounded. Note that the company MITERA has filed a counter lawsuit against the same maternity hospital and other defendants before the Athens Multi-Member Court of First Instance, asking that the hospital and the other defendants be held jointly and severally liable and must be made to pay the amount of €18m as compensation for moral harm. The Company's Management and legal advisors estimate that the said lawsuit is well-founded and will be accepted.

OTHER SUBSIDIARIES
The HYGEIA Group companies (both as a defendant and as a plaintiff) are involved in various pending court cases as part of their normal operation. On September 30th, 2012, the Group's other subsidiaries had formed a provision of €0.7m. The Group companies' Management and legal advisors estimate that the pending cases, apart from the already formed provision for *sub judice* cases, are expected to be settled without a significant negative impact on the Group's consolidated financial position or their operating results.

Among the aforementioned pending court cases, there is a lawsuit filed by a private maternity hospital against subsidiary LETO and other maternity hospitals before the Athens Multi-Member Court of First Instance, asking that the Company and the other maternity hospitals be held jointly and severally liable and must be made to pay the amount of €10m as compensation for moral harm. The Company's Management and legal advisors estimate that the said lawsuit will be rejected as unfounded. Note that subsidiary LETO has filed a counter lawsuit against the same maternity hospital and other defendants before the Athens Multi-

Member Court of First Instance, asking that the hospital and the other defendants be held jointly and severally liable and must be made to pay the amount of €18m as compensation for moral harm. The Company's Management and legal advisors estimate that the said lawsuit is well-founded and will be accepted.

Minority shareholders of VALLONE Group subsidiary CHRYSAFILIOTISSA PUBLIC LTD have filed a lawsuit against the companies CHRYSAFILIOTISSA PUBLIC LTD, CHRYSAFILIOTISSA INVESTMENT LTD and VALLONE CO LTD to annul the decision by the Extraordinary General Meeting and the BoD of CHRYSAFILIOTISSA PUBLIC LTD to increase its share capital, claiming €15m in compensation. On April 12th, 2012, by decision of the Nicosia District Court, the application filed by the aforementioned shareholders for an interim order in the context of the aforementioned lawsuit was rejected. The company's legal advisors, having taken the aforementioned decision into account, estimate that the lawsuit is vague and unfounded, and will be rejected.

17.5 Contingent tax liabilities

The unaudited tax years for the Group companies are outlined in Note II.2.

With regard to the Group companies active in Greece, a tax audit was completed in July 2012 and the relevant tax certificates have been issued. From the aforementioned audit, no additional tax liabilities arose that may have a material impact on the Financial Statements of the companies and the Group.

In relation to the unaudited tax periods mentioned above, there is a possibility that additional tax and surcharges could be imposed when they are examined and finalized. Each year, the Group assesses contingent liabilities which are expected to arise from past fiscal year audits, by forming provisions where this is deemed necessary. The Management considers that other than the formations made, any tax amounts which may arise will not have a major impact on the Group's net position, fiscal year results and cash flows.

17.6 Other commitments

Other commitments of the Group on September 30th, 2012 and December 31st, 2011 were as follows:

	GROUP	
Amounts in € '000	**30/9/2012**	**31/12/2011**
Other commitments		
Within one year	889	896
After one year but not more than five years	2,325	2,897
More than five years	291	462
Total other commitments	**3,505**	**4,255**

The other commitments of the Group pertain to commitments for the purchase of medical equipment by subsidiary HYGEIA Hospital Tirana.

The Company did not have any other commitments either on September 30th, 2012 or during the period being compared.

18. Transactions with related parties

Intercompany transactions

The following transactions and balances are the transactions of the Group's subsidiaries. These transactions among the companies included in the Group's consolidated Financial Statements are crossed out during the process of full consolidation.

INTERCOMPANY PURCHASES - SALES 1.1.2012 - 30.09.2012

SELLER

BUYER	DTCA HYGEIA SA	MITERA SA	LETO SA	LETO HOLDINGS SA	ALFA LAB SA	HYGEIA HOSPITAL TIRANA SA	STEM HEALTH SA	STEM HEALTH HELLAS SA	LOGIMED Sh.p.k.	Y-LOGIMED SA	Y- PHARMA SA	ANIZ SA	VALLONE CO LTD	EVANGELISMOS MANAGEMENT LTD	BIOCHECK SA	PRIMARY MEDICINE SA	TOTAL
DTCA HYGEIA SA	0	1,692,034	1,635	6,537	0	150,394	0	35,254	0	49,470	0	47,748	0	805	770	100	1,984,747
MITERA SA	75,593	0	2,394	0	0	15,408	0	104,195	0	3,321	0	0	0	0	1,423	0	202,334
LETO SA	0	3,579	0	1,384	18,172	0	0	25,620	0	725	0	0	0	0	0	0	49,480
ALFA LAB SA	251,134	45,620	102,768	0	0	200	0	0	0	0	0	0	0	0	10,832	745	411,299
HYGEIA HOSPITAL TIRANA SA	16,483	0	0	0	0	0	0	0	344,523	0	0	0	0	0	0	0	361,006
STEM HEALTH SA	0	0	0	0	0	0	0	69,119	0	0	0	0	0	0	0	0	69,119
STEM HEALTH HELLAS SA	0	0	0	0	0	69,399	1,800	0	0	0	0	0	0	0	0	0	71,199
LOGIMED Shpk	0	0	0	0	0	1,002,671	0	0	0	45,575	0	0	0	0	0	0	1,048,246
Y-LOGIMED SA	15,001,888	5,458,239	973,620	0	4,183	363,120	0	7,179	471,535		288	0	2,856	7,842	18,201	96,863	22,405,814
Y- PHARMA SA	410,034	148,338	40,009	0	0	0	0	0	0	799	0	0	0	0	0	0	599,180
ANIZ SA	19,215	0	0	0	0	0	0	0	0	57	0	0	0	0	0	0	19,272
VALLONE CO LTD	0	0	0	0	0	0	0	0	0	0	0	0	0	14,317	0	0	14,317
AKESO PROPERTY LTD	0	0	0	0	0	0	0	0	0	0	0	0	0	75,900	0	0	75,900
EVANGELISMOS MANAGEMENT LTD	0	0	0	0	0	0	0	0	0	0	0	0	4,415	0	0	0	4,415
BIOCHECK SA	103,741	0	0	0	10	0	0	0	0	0	0	0	0	0	0	0	103,751
PRIMARY MEDICINE	102,313	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	102,313
TOTAL	**15,980,401**	**7,347,810**	**1,120,426**	**7,921**	**22,365**	**1,601,192**	**1,800**	**241,367**	**816,058**	**99,947**	**288**	**47,748**	**7,271**	**98,864**	**31,226**	**97,708**	**27,522,392**

SELLER

BUYER	DTCA HYGEIA SA	MITERA SA	LETO SA	LETO HOLDINGS SA	ALFA LAB SA	HYGEIA HOSPITAL TIRANA SA	STEM HEALTH SA	STEM HEALTH HELLAS SA	LOGIMED Sh.p.k.	Y-LOGIMED SA	Y- PHARMA SA	ANIZ SA	VALLONE CO LTD	EVANGELISMOS MANAGEMENT LTD	BIOCHECK SA	PRIMARY MEDICINE SA	TOTAL
DTCA HYGEIA SA	0	2,144,830	19,510	5,300	0	488,682	0	33,768	0	5,209	0	92,510	730	871	0	0	2,791,410
MITERA SA	73,090	0	1,479	0	278	12,261	0	76,994	0	0	0	0	0	300	0	0	164,402
MITERA HOLDINGS SA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LETO SA	0	0	0	1,373	18,468	0	0	0	0	0	0	0	0	0	52,950	75,632	148,423
LETO HOLDINGS SA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ALFA LAB SA	288,599	57,256	115,828	0	0	330	0	0	0	0	0	0	0	0	15,556	2,233	479,802
HYGEIA HOSPITAL TIRANA SA	0	0	0	0	0	0	0	0	2,850	0	0	0	0	0	0	0	2,850
STEM HEALTH SA	0	0	0	0	0	0	0	80,383	0	0	0	0	0	0	0	0	80,383
STEM HEALTH HELLAS SA	0	271,120	126,870	0	0	0	1,800	0	0	0	0	0	0	0	0	0	399,790
LOGIMED Shpk	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Y-LOGIMED SA	15,661,737	5,481,407	894,878	0	3,525	662,664	0	36,132	246	0	16,784	0	14,155	4,558	17,222	44,718	22,838,026
Y- PHARMA SA	1,117,644	921,435	220,372	0	0	0	0	0	0	1,288	0	0	1,876	109	0	0	2,262,724
ANIZ SA	22,086	2,950	350	0	0	0	0	0	0	221	0	0	0	0	0	0	25,607
VALLONE CO LTD	0	6,028	0	0	0	0	0	0	0	0	0	0	0	26,573	0	0	32,601
AKESO PROPERTY LTD	0	0	0	0	0	0	0	0	0	0	0	0	0	227,700	0	0	227,700
EVANGELISMOS MANAGEMENT LTD	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIOCHECK SA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,150	1,150
PRIMARY MEDICINE	0	481	0	0	0	0	0	0	0	0	0	0	0	0	29,743	0	30,224
TOTAL	**17,163,156**	**8,885,507**	**1,379,287**	**6,673**	**22,271**	**1,163,937**	**1,800**	**227,277**	**3,096**	**6,718**	**16,784**	**92,510**	**16,761**	**260,111**	**115,471**	**123,733**	**29,485,092**

INTERCOMPANY RECEIVABLES - LIABILITIES ON 31.09.2012

RECEIVABLE

LIABILITY	DTCA HYGEIA SA	MITERA SA	LETO SA	LETO HOLDINGS SA	ALFA LAB SA	HYGEIA HOSPITAL TIRANA SA	STEM HEALTH HELLAS SA	Y-LOGIMED SA	LOGIMED Shpk	Y- PHARMA SA	VALLONE CO LTD	EVANGELISMOS MGC LTD	EVANGELISMOS PROPERTY SA	AKESO PROPERTY SA	EVANGELISMOS MANAGEMENT LTD	BIOCHECK SA	PRIMARY MEDICINE SA	TOTAL
DTCA HYGEIA SA	0	5,904,371	20,906	8,610	197,200	1,538,494	171,898	216,938	0	3,088	8,392	100,000	0	0	55,667	947	123	8,226,634
MITERA SA	-5,310	0	8,366	0	278	207,368	811,738	3,796	0	0	40,052	0	0	0	0	1,751	1,000	1,069,039
LETO SA	0	0	0	0	0	0	77,278	0	0	0	0	0	0	0	0	52,950	5,916	136,144
LETO HOLDINGS SA	0	0	79,134	0	0	0	0	0	0	0	0	0	0	0	0	0	0	79,134
ALFA LAB SA	23,695	45,620	82,726	0	0	200	0	0	0	0	0	0	0	0	0	14,608	815	167,664
HYGEIA HOSPITAL TIRANA SA	16,483	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	16,483
STEM HEALTH SA	0	0	0	0	0	0	528,548	0	0	0	0	0	0	0	0	0	0	528,548
STEM HEALTH HELLAS SA	0	5,954	56,353	0	0	23,125	0	0	0	0	0	0	0	0	0	0	0	85,432
Y-LOGIMED SA	12,947,032	6,563,822	1,276,939	0	0	851,196	54,050	0	533,732	355	5,717	0	0	0	19,522	175,012	1,112,498	23,545,019
LOGIMED Shpk	0	0	0	0	5,144	457,973	0	45,575	0	0	0	0	0	0	0	0	0	503,548
Y- PHARMA SA	324,966	44,579	21,558	0	0	0	0	190	0	0	0	0	0	0	0	0	0	391,293
ANIZ SA	19,520	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	19,590
VALLONE CO LTD	0	7,489	0	0	0	0	0	0	0	0	0	0	0	0	16,818	0	0	24,307
EVANGELISMOS MGC LTD	0	0	0	0	0	0	0	0	0	0	0	0	0	310,571	123,019	0	0	433,590
EVANGELISMOS PROPERTY LTD	0	0	0	0	0	0	0	0	0	0	0	0	0	1,700	0	0	0	1,700
AKESO PROPERTY LTD	0	0	0	0	0	0	0	0	0	0	0	33,933	2,625	0	0	0	0	36,558
EVANGELISMOS MANAGEMENT LTD	0	0	0	0	0	0	0	0	0	0	0	226,202	7,094	1,884,080	0	0	0	2,117,376
BIOCHECK SA	14,288	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	14,298
PRIMARY MEDICINE SA	13,376	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,479	0	15,855
TOTAL	**13,354,050**	**12,571,835**	**1,545,982**	**8,610**	**202,622**	**3,078,356**	**1,643,512**	**266,569**	**533,732**	**3,443**	**54,161**	**360,135**	**9,719**	**2,196,351**	**215,026**	**247,747**	**1,120,352**	**37,412,212**

INTERCOMPANY RECEIVABLES - LIABILITIES ON 31.12.2011

RECEIVABLE

LIABILITY	DTCA HYGEIA SA	MITERA SA	LETO SA	LETO HOLDINGS SA	ALFA LAB SA	HYGEIA HOSPITAL TIRANA SA	STEM HEALTH HELLAS SA	LOGIMED Shpk	Y-LOGIMED SA	Y- PHARMA SA	VALLONE CO LTD	EVANGELISMOS MGC LTD	EVANGELISMOS PROPERTY SA	AKESO PROPERTY SA	EVANGELISMOS MANAGEMENT LTD	BIOCHECK SA	PRIMARY MEDICINE SA	TOTAL
DTCA HYGEIA SA	0	4,581,457	91,038	8,610	197,200	17,149,725	135,375	0	159,637	3,088	8,392	0	0	0	44,862	0	0	22,379,384
MITERA SA	133,735	0	5,973	0	278	191,960	707,428	0	764	0	40,052	0	0	0	0	0	1,000	1,081,190
LETO SA	0	3,074	0	834	0	0	121,658	0	0	0	0	0	0	0	0	52,950	5,916	184,432
LETO HOLDINGS SA	3,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,000
ALFA LAB SA	19,950	33,586	17,465	0	0	730	0	0	0	0	0	0	0	0	0	5,621	1,200	78,581
HYGEIA HOSPITAL TIRANA SA	0	0	0	0	0	0	0	3,800	0	0	0	0	0	0	0	0	0	3,800
STEM HEALTH SA	0	0	0	0	0	0	630,330	0	0	0	0	0	0	0	0	0	0	630,330
STEM HEALTH HELLAS SA	0	18,954	126,353	0	0	0	0	0	0	0	0	0	0	0	0	0	0	145,307
LOGIMED Shpk	0	0	0	0	0	34,284	0	0	0	0	0	0	0	0	0	0	0	34,284
Y-LOGIMED SA	8,418,361	4,369,147	707,925	0	2,296	586,725	48,220	62,197	0	7,173	2,861	0	0	0	9,876	25,726	1,176,635	15,417,143
Y- PHARMA SA	147,462	50,237	8,697	0	0	0	0	0	1,091	0	0	0	0	0	0	0	0	207,487
ANIZ SA	13,195	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	13,195
VALLONE CO LTD	81,749	7,489	0	0	0	0	0	0	0	0	0	0	0	0	17,621	0	0	106,859
EVANGELISMOS MGC LTD	0	0	0	0	0	0	0	0	0	0	0	0	0	310,572	123,019	0	0	433,591
EVANGELISMOS PROPERTY LTD	0	0	0	0	0	0	0	0	0	0	0	0	0	1,700	0	0	0	1,700
AKESO PROPERTY LTD	0	0	0	0	0	0	0	0	0	0	0	33,933	2,625	0	0	0	0	36,558
EVANGELISMOS MANAGEMENT LTD	0	0	0	0	0	0	0	0	0	0	0	605,382	3,826	1,628,725	0	0	0	2,237,933
BIOCHECK SA	3,655	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,655
PRIMARY MEDICINE SA	6,832	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12,393	0	19,225
TOTAL	**8,827,939**	**9,063,944**	**957,451**	**9,444**	**199,774**	**17,963,424**	**1,643,011**	**65,997**	**161,492**	**10,261**	**51,305**	**639,315**	**6,451**	**1,940,997**	**195,378**	**96,720**	**1,184,751**	**43,017,654**

Transactions with related parties

Amounts in €'000	GROUP 30/9/2012	COMPANY 30/9/2012	GROUP 30/9/2011	COMPANY 30/9/2011
Sale of products/services				
Subsidiaries	0	1,685	0	2,065
Other related parties	299	6	338	25
Total	**299**	**1,691**	**338**	**2,090**

Amounts in €'000	GROUP 30/9/2012	COMPANY 30/9/2012	GROUP 30/9/2011	COMPANY 30/9/2011
Other income/income from holdings				
Subsidiaries	0	300	0	727
Other related parties	9	9	21	21
Total	**9**	**309**	**21**	**748**

Amounts in €'000	GROUP 30/9/2012	COMPANY 30/9/2012	GROUP 30/9/2011	COMPANY 30/9/2011
Purchase of products				
Subsidiaries	0	14,764	0	16,152
Total	**0**	**14,764**	**0**	**16,152**

Amounts in €'000	GROUP 30/9/2012	COMPANY 30/9/2012	GROUP 30/9/2011	COMPANY 30/9/2011
Other expenses				
Subsidiaries	0	1,217	0	1,011
Other related parties	4,743	2,932	4,977	2,951
Total	**4,743**	**4,149**	**4,977**	**3,962**

Amounts in €'000	GROUP 30/9/2012	COMPANY 30/9/2012	GROUP 30/9/2011	COMPANY 30/9/2011
Purchase of tangible/intangible assets				
Other related parties	929	696	437	418
Total	**929**	**696**	**437**	**418**

Amounts in €'000	GROUP 30/9/2012	COMPANY 30/9/2012	GROUP 31/12/2011	COMPANY 31/12/2011
Receivables				
Subsidiaries	0	8,227	0	22,379
Other related parties	48	3	121	98
Total	**48**	**8,229**	**121**	**22,477**

Amounts in €'000	GROUP 30/9/2012	COMPANY 30/9/2012	GROUP 31/12/2011	COMPANY 31/12/2011
Liabilities				
Subsidiaries	0	13,354	0	8,828
Other related parties	2,097	613	1,694	760
Total	**2,097**	**13,967**	**1,694**	**9,588**

Compensation paid to key management and administrative executives

The compensation paid to key management and administrative executives can be broken down as follows:

Amounts in € '000	GROUP		COMPANY	
	30/9/2012	30/9/2011	30/9/2012	30/9/2011
Salaries & other employees benefits	3,121	3,667	1,082	1,221
Social security costs	364	408	148	148
B.O.D. Remuneration	0	48	0	0
Termination benefits	67	104	0	32
Total	**3,552**	**4,227**	**1,230**	**1,401**

No loans have been granted to any members of the Board or any other executives of the Group (or their families).

19. Earnings per share

In order to determine the earnings per share, profit was divided by the weighted average number of ordinary shares.

Amounts in €

Continuing operations	GROUP		COMPANY	
Basic earnings / (loss) per share	**30/9/2012**	**30/9/2011**	**30/9/2012**	**30/9/2011**
Earnings attributable to equity holders of the parent company	(12,027,417)	(21,174,645)	3,004,679	(2,940,822)
Weighted average number of shares	305,732,436	175,861,651	305,732,436	175,861,651
Basic earnings / (loss) per share (Euro per share)	**(0.0393)**	**(0.1204)**	**0.0098**	**(0.0167)**

Amounts in €

Discontinued operations	GROUP	
Basic earnings / (loss) per share	**30/9/2012**	**30/9/2011**
Earnings attributable to equity holders of the parent company	0	(6,243,607)
Weighted average number of shares	305,732,436	175,861,651
Basic earnings / (loss) per share (Euro per share)	**0.0000**	**(0.0355)**

20. Events after the end of the reporting period

There are no events subsequent to the Financial Statements that relate to either the Group or the Company and which must be reported pursuant to the IFRS.

21. Approval of condensed interim Financial Statements

The condensed interim company and consolidated Financial Statements for the period ended on September 30th, 2012 were approved by the BoD of DIAGNOSTIC AND THERAPEUTIC CENTER OF ATHENS HYGEIA SA on November 21, 2012.

Marousi, November 21st, 2012

THE VICE-CHAIRMAN OF THE BOARD

GEORGIOS POLITIS
ID Card No. M322901

THE CEO

ARETI SOUVATZOGLOU
ID Card No. AI091976

THE CHIEF FINANCIAL OFFICER OF THE GROUP

DIMITRIOS MANTZAVINOS
ID Card No. N294701

THE DEPUTY CHIEF FINANCIAL OFFICER OF THE GROUP

SPYRIDON KOSMAS
ID Card No. AZ555377
LICENSE No. 16310-CLASS A

THE FINANCIAL CONTROLLER OF THE GROUP

NIKOLAOS LEKAKIS
ID Card No. AE106335

E. DATA AND INFORMATION

DIAGNOSTIC AND THERAPEUTIC CENTER OF ATHENS HYGEIA SA
Companies Reg. No. 13165/06/B/86/14
KIFISIAS AVENUE & 4 ERYTHROU STAVROU STREET, MAROUSI 15123, ATHENS
Data and information for the period January 1, 2012 to September 30, 2012
(in accordance with Decision 4/507/28.4.2009 of the BoD of the Hellenic Capital Market Commission)

These data and information aim to provide a general overview of the financial status and results of DIAGNOSTIC AND THERAPEUTIC CENTER OF ATHENS HYGEIA SA. Consequently, we recommend that before making any investment decision or engaging in any transaction with the Company, readers should consult the issuer's website where the financial statements have been posted along with the review report of the statutory auditor wherever that is required.

GENERAL INFORMATION ABOUT THE COMPANY

Website:	www.hygeia.gr
Date of approval of Interim Financial Statements by BoD:	November 21, 2012

STATEMENT OF FINANCIAL POSITION (CONSOLIDATED AND SEPARATE DATA)
(amounts in thousands of €)

	Group		Company	
	30/9/2012	31/12/2011	30/9/2012	31/12/2011
ASSETS				
Property, plant and equipment	250,097	256,494	96,234	100,172
Investment property	160	162	160	162
Intangible assets	132,271	133,496	2,558	2,686
Other non-current assets	173,408	173,195	325,235	325,272
Inventories	6,775	7,502	1,716	1,753
Accounts receivable	103,813	74,716	74,474	58,115
Other current assets	45,381	50,449	34,373	34,153
TOTAL ASSETS	**711,905**	**696,014**	**534,750**	**522,313**
EQUITY & LIABILITIES				
Share capital	125,350	125,350	125,350	125,350
Other equity items	197,448	208,987	249,306	246,301
Equity attributable to owners of parent company (a)	**322,798**	**334,337**	**374,656**	**371,651**
Non-controlling interests (b)	15,585	19,014	0	0
Total equity (c) = (a) + (b)	**338,383**	**353,351**	**374,656**	**371,651**
Long-term borrowings	105,757	11,524	95,000	0
Provisions / Other long-term liabilities	72,877	71,478	17,354	16,831
Short-term borrowings	95,810	180,974	0	95,000
Other short-term liabilities	99,078	78,687	47,740	38,831
Total liabilities (d)	**373,522**	**342,663**	**160,094**	**150,662**
TOTAL EQUITY AND LIABILITIES (c) + (d)	**711,905**	**696,014**	**534,750**	**522,313**

STATEMENT OF FINANCIAL POSITION (CONSOLIDATED AND SEPARATE DATA)
(amounts in thousands of €)

	Group 1/1-30/9/2012		
	Continuing operations	Discontinued operations	Total
Revenues	184,511	0	184,511
Gross profit	18,025	0	18,025
Earnings before taxes, financing & investing	(2,832)	0	(2,832)
Earnings / (losses) before tax	(12,973)	0	(12,973)
Profits / (losses) after tax (A)	(14,715)	0	(14,715)
- Parent company owners	(12,027)	0	(12,027)
- Non-controlling interests	(2,688)	0	(2,688)
Other comprehensive income after tax (b)	(214)	0	(214)
Total comprehensive income after tax (A) +(B)	(14,929)	0	(14,929)
- Parent company owners	(12,192)	0	(12,192)
- Non-controlling interests	(2,737)	0	(2,737)
Basic earnings / (losses) per share after tax (in €)	(0.0393)	0	(0.0393)
Earnings before taxes, financing & investing and total depreciation	12,298	0	12,298

	Group 1/1-30/9/2011		
	Continuing operations	Discontinued operations	Total
Revenues	184,183	2,157	186,340
Gross Profit / (losses)	8,119	(350)	7,769
Earnings / (losses) before taxes, financing & investing	(12,381)	(664)	(13,045)
Earnings / (losses) before tax	(23,850)	(1,107)	(24,957)
Profits / (losses) after tax (A)	(25,117)	(7,077)	(32,194)
- Parent company owners	(21,175)	(6,244)	(27,419)
- Non-controlling interests	(3,942)	(833)	(4,775)
Other comprehensive income after tax (b)	454	0	454
Total comprehensive income after tax (A) +(B)	(24,663)	(7,077)	(31,740)
- Parent company owners	(21,027)	(6,244)	(27,271)
- Non-controlling interests	(3,636)	(833)	(4,469)
Basic earnings / (losses) per share after tax (in €)	(0.1204)	(0.0355)	(0.1559)
Earnings / (losses) before taxes, financing and investing and total depreciation	1,692	(492)	1,200

	Group 1/7-30/9/2012		
	Continuing operations	Discontinued operations	Total
Revenues	56,692	0	56,692
Gross profit	3,361	0	3,361
Earnings / (losses) before taxes, financing & investing	(3,776)	0	(3,776)
Earnings / (losses) before tax	(7,508)	0	(7,508)
Profits / (losses) after tax (A)	(7,225)	0	(7,225)
- Parent company owners	(6,461)	0	(6,461)
- Non-controlling interests	(764)	0	(764)
Other comprehensive income after tax (b)	(331)	0	(331)
Total comprehensive income after tax (A) +(B)	(7,556)	0	(7,556)
- Parent company owners	(6,751)	0	(6,751)
- Non-controlling interests	(805)	0	(805)
Basic earnings / (losses) per share after tax (in €)	(0.0211)	0	(0.0211)
Earnings before taxes, financing & investing and total depreciation	1,362	0	1,362

	Group 1/7-30/9/2011		
	Continuing operations	Discontinued operations	Total
Revenues	55,972	0	55,972
Gross profit	(260)	0	(260)
Earnings / (losses) before taxes, financing & investing	(6,984)	0	(6,984)
Earnings / (losses) before tax	(10,602)	0	(10,602)
Profits / (losses) after tax (A)	(11,387)	0	(11,387)
- Parent company owners	(10,186)	0	(10,186)
- Non-controlling interests	(1,201)	0	(1,201)
Other comprehensive income after tax (b)	60	0	60
Total comprehensive income after tax (A) +(B)	(11,327)	0	(13,648)
- Parent company owners	(10,137)	0	(10,137)
- Non-controlling interests	(1,190)	0	(1,190)
Basic earnings / (losses) per share after tax (in €)	(0.0579)	0.0000	(0.0579)
Earnings before taxes, financing a& investing and total depreciation	(2,101)	0	(2,101)

	Company			
	1/1-30/9/2012	1/1-30/9/2011	1/7-30/9/2012	1/7-30/9/2011
Revenues	102,902	107,134	30,252	31,594
Gross profit	14,687	15,575	2,322	3,285
Earnings before taxes, financing & investing	8,805	9,851	383	1,466
Earnings / (losses) before tax	4,159	(2,496)	(1,267)	(762)
Profits / (losses) after tax (A)	3,005	(2,941)	(882)	(1,270)
Other comprehensive income after tax (b)	0	0	0	0
Total comprehensive income after tax (A) +(B)	3,005	(2,941)	(882)	(1,270)
Basic earnings / (losses) per share after tax (in €)	0.0098	(0.0167)	(0.0029)	(0.0072)
Earnings before taxes, financing & investing and total depreciation	15,565	15,769	2,588	3,491

STATEMENT OF CASH FLOWS (CONSOLIDATED AND SEPARATE DATA)
(amounts in thousands of €)

	Group		Company	
	1/1-30/9/2012	1/1-30/9/2011	1/1-30/9/2012	1/1-30/9/2011
Operating activities				
Earnings / (losses) before taxes (from continuing operations)	(12,973)	(23,850)	4,159	(2,496)
Earnings / (losses) before taxes (from discontinued operations)	0	(6,945)	0	0
Plus/Minus adjustments for:				
Depreciation	15,225	14,242	6,929	5,950
Provisions	1,947	2,002	1,035	1,044
Reversal of prior year's provisions	(198)	(739)	0	0
Foreign exchange differences	236	540	14	0
Results (income, expenses, profits & losses) from investing activities	773	395	(157)	5,852
Amortization of grants - concession of rights	(121)	(123)	(30)	(30)
Interest charges and related expenses	10,146	11,465	5,220	7,063
Decrease / (increase) in inventories	566	1,153	36	785
Decrease / (increase) in receivables	(29,725)	(995)	(15,506)	(9,113)
(Increase) / Decrease in other currents assets accounts	(527)	5,050	(3,061)	281
(Decrease) /increase in liabilities (excl. banks)	18,307	(5,263)	7,512	(2,228)
Operating cash flows from discontinued operations	0	6,834	0	0
Less:				
Interest charges and related expenses paid	(10,105)	(10,792)	(5,563)	(6,489)
Tax paid	(270)	(2,385)	0	(463)
Total inflow / (outflow) from operating activities (a)	**(6,719)**	**(9,410)**	**588**	**156**
Investing activities:				
Purchase of intangible and tangible assets	(8,027)	(10,660)	(4,139)	(5,366)
Proceeds on sale of intangible and tangible assets	25	212	1,414	31
Purchase of subsidiaries (less subsidiary's cash balance)	0	6,542	0	6,931
Grants received	21	0	0	0
Loans granted to related parties	0	0	0	(125)
Proceeds from loans granted to related parties	0	0	0	9,025
Interest received	432	281	385	176
Parent company share capital increase	0	0	0	(76)
Dividends received	0	0	50	36
Investing cash flows from discontinued operations	0	2,048	0	0
Total inflow / (outflow) from investing activities (b)	**(7,549)**	**(1,576)**	**(2,290)**	**10,632**
Financing activities				
Share capital increase expenses	0	(707)	0	(707)
Proceeds from loans issued / taken out	31,247	93,529	0	60,000
Loan repayment	(21,551)	(77,556)	0	(67,000)
Leasing arrangement liabilities paid (instalments)	(627)	(590)	0	0
Dividends paid	(39)	(20)	0	0
Financing cash flows from discontinued operations	0	(2,099)	0	0
Total inflow / (outflow) from financing activities (c)	**9,030**	**12,559**	**0**	**(7,707)**
Net increase/(decrease) in cash and cash equivalents for the period (a)+(b)+(c)	**(5,238)**	**1,573**	**(1,702)**	**3,081**
Cash and cash equivalents at the beginning of period from continuing operations	37,375	35,469	29,566	27,001
Cash and cash equivalents at the beginning of period from discontinued operations	0	582	0	0
Foreign exchange differences in cash and cash equivalents from continuing operations	(12)	(52)	0	0
Foreign exchange differences in cash and cash equivalents from discontinued operations	0	(33)	0	0
Cash and cash equivalents at end of period	**32,125**	**37,539**	**27,864**	**30,082**

STATEMENT OF CHANGES IN EQUITY (CONSOLIDATED AND SEPARATE DATA)
(amounts in thousands of €)

	Group		Company	
	30/9/2012	30/9/2011	30/9/2012	30/9/2011
Total equity at the beginning of period (1/1/2012 and 1/1/2011 respectively)	353,351	326,149	371,651	320,112
Total comprehensive income after tax (from continuing and discontinued operations)	(14,929)	(31,740)	3,005	(2,941)
Share capital increase expenses	0	(730)	0	(730)
Dividends to non-controlling interests in subsidiaries	(39)	(20)	0	0
Decrease in non-controlling interests from sale of subsidiaries	0	4,598	0	0
Total equity at end of period (30/6/2012 and 30/6/2011 respectively)	**338,383**	**298,257**	**374,656**	**316,441**

ADDITIONAL DATA AND INFORMATION

1. The Financial Statements have been prepared in accordance with the accounting policies used to prepare the Annual Financial Statements for the fiscal year ended December 31, 2011, apart from the changes in the Standards and Interpretations effective as of January 1, 2012 and outlined in Note II.4 of the Interim Financial Statements.
2. The separate and consolidated Cash Flow Statements have been prepared using the indirect method.
3. All intercompany transactions and balances of the companies included in the consolidation have been crossed out in the Group's financial statements.
4. The companies in the Group, and their respective holdings, as well as the consolidation method used to include them in the consolidated financial statements for the period January 1 to September 30, 2012, are explained in detail in Note II.2 of the Interim Financial Statements.
5. Compared to the same period in 2011, GENESIS Group has not been included in the consolidated Financial Statements for the period ended September 30, 2012, due to the fact that it was sold off and the Group lost control of it by means of a contract signed on February 14, 2011.
6. The Company's Consolidated Financial Statements have been included in the Consolidated Financial Statements as at September 30, 2012 prepared by MARFIN INVESTMENT GROUP HOLDINGS SA, which is registered in Greece, using the full consolidation method and a consolidation percentage of 70.38%.
7. The Company has formed an accumulated provision of €1.4m and the Group a similar provision amounting to approximately €9.5m for disputes which are *sub judice* or in arbitration, or for decisions / judgments of judicial or administrative bodies which have or may have serious implications for the Company and the Group's financial situation or operations. These pertain to claims by patients or their heirs, part of which are covered by the insurance payout payable by the insurance companies doctors hold malpractice liability policies with. Substantial added burdens arising from other disputes *sub judice* or in arbitration for the Company and the Group, or from court judgments which will entail the provision already formed being exceeded (Note II.17.4 of the Interim Financial Statements) are not expected.
8. The company has been audited for taxation purposes up to and including the 2008 fiscal year. The open (unaudited) fiscal years for the Group's companies are explained in detail in Note II.2 of the Interim Financial Statements. The Company has an established accumulated provision amounting to €450,000 for open fiscal years. The respective provision for the Group is approximately €2.4m.
9. On September 30, 2012, the Group employed a total of 3,406 people (September 30, 2011: 3,408) and the Company a total of 1,284 (September 30, 2011: 1,257).
10. The income/expenses for the period January 1, 2012 to September 30, 2012, as well as the receivables/liabilities balances as at September 30, 2012 resulting from transactions with related parties, as defined in IAS 24, are outlined in the following table:

Intercompany transactions/Balances and other related parties	Group	Company
Income	309	2,000
Expenses	5,672	19,609
Receivables	48	8,230
Liabilities	2,097	13,967
Transactions & remuneration for management and executives	3,552	1,230

11. On September 30, 2012, the mortgages registered on HYGEIA properties as collateral against loans amounted to €72m. In addition, on September 30, 2012, the mortgages registered on HYGEIA Group properties as collateral for loans amounted to €34.8m.
12. Other comprehensive income for the period January 1 to September 30, 2012 amounted to €214,000 and mainly pertained to the exchange-rate differences arising from converting the Financial Statements of subsidiaries to the parent company's operating currency (euro). Respectively, other total income for the period January 1 to September 30, 2011 amounted to €454,000.
13. On September 28, 2012, the Company signed a common corporate bond loan amounting to €95m with the associated banks Piraeus, Eurobank Ergasias, Emporiki and Alpha Bank. It is a five-year loan with a floating interest rate based on Euribor plus margin.
14. The Group and Company Financial Statements for September 30, 2012 were approved by the Company's Board of Directors on November 21, 2012.
15. At the end of the current period, there were no parent company treasury shares that were owned either by the parent company itself or by its subsidiaries or affiliated companies.
16. Earnings/(losses) per share were calculated based on the allocation of earnings/(losses) after taxes and non-controlling interests over the total weighted number of parent company shares.
17. There are no events subsequent to the Financial Statements that relate to either the Group or the Company which must be reported pursuant to the IFRS, apart from those mentioned in Note II.20 of the Interim Financial Statements.

Marousi, November 21, 2012

BoD VICE-CHAIRMAN	CHIEF EXECUTIVE OFFICER	GROUP CHIEF FINANCIAL OFFICER	GROUP DEPUTY CHIEF FINANCIAL OFFICER	GROUP FINANCIAL CONTROLLER
GEORGIOS POLITIS ID No. M322901	ARETI SOUVATZOGLOU ID No. AI091976	DIMITRIOS MANTZAVINOS ID No. N294701	SPYRIDON KOSMAS ID No. AZ555377 LICENSE No. 16310-CLASS A	NIKOLAOS LEKAKIS ID No. AE106335